News & Updates

Second-line antibody-drug conjugate in a patient with HR-positive, HER2-low advanced breast cancer

21 Feb 2025 by

A 56-year-old woman who is a smoker with a history of endometriotic cyst and no family history of cancers was diagnosed in 2015 with T2N1, hormone receptor (HR)–positive, HER2-negative right breast cancer. Baseline PET-CT scan showed suspicious bone metastasis at T2, which was unconfirmed histologically. She was premenopausal at diagnosis with an Eastern Cooperative Oncology Group performance status (PS) of 0.

Second-line antibody-drug conjugate in a patient with HR-positive, HER2-low advanced breast cancer

21 Feb 2025

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025 by

Occurring in up to 20 percent of breast cancers, HER2 overexpression is linked to high disease recurrence and poor survival outcomes. At the Hong Kong Breast Cancer Foundation (HKBCF) Annual Breast Cancer Updates 2024 meeting, Professor Matteo Lambertini from University of Genova, Italy, discussed the benefits of adding pertuzumab to trastuzumab and chemotherapy in managing HER2-positive (HER2+) early breast cancer (EBC), while a real-world case was shared by Dr Josephine Tsang from Queen Mary Hospital, Hong Kong.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

12 Feb 2025 by

A 59-year-old female was referred to our clinic in 2017 with a confirmed diagnosis of chronic lymphocytic leukaemia (CLL). Her Eastern Cooperative Oncology Group performance status was 0. She had dyslipidaemia for which she was receiving statin therapy, but no other remarkable history.

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

12 Feb 2025

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

08 Feb 2025 by

A 45-year-old premenopausal female who was otherwise healthy presented in September 2020 with a lump, which was the size of an egg yolk, in her right breast. Diagnostic workup revealed multiple irregularly edged masses in the right breast, with the largest located in the upper outer quadrant measuring approximately 37 x 21 mm, and multiple enhanced lymph nodes (LNs) of approximately 13 x 10 mm in the right armpit. Biopsy of the breast mass and LNs showed invasive HER2-positive and hormone receptor (HR)–positive (both oestrogen receptor– and progesterone receptor–positive) ductal carcinoma, with a Ki-67 level of 20 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT2NxM0).

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

08 Feb 2025

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

07 Feb 2025 by

A 43-year-old premenopausal female presented with a left breast mass in April 2022. She had good past health and an excellent performance status. A biopsy showed invasive ductal carcinoma (IDC) that was weakly hormone receptor–positive (oestrogen receptor [ER], 4/8; progesterone receptor [PR], 3/8) and human epidermal growth factor receptor-2–negative (HER2-) with a Ki-67 proliferation index of 60 percent. A PET-CT scan performed at the time of initial diagnosis showed no distant metastases, and the tumour was clinically staged as cT2N0M0. Immediate resection was not feasible as the growth was attached to the underlying muscle.

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

07 Feb 2025

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025 by

HER2-low metastatic breast cancer (mBC) is a heterogeneous disease with diverse clinicopathological characteristics and limited later-line treatment options. During an industry-sponsored symposium organized by the Hong Kong Breast Oncology Group, Dr Erika Hamilton of Sarah Cannon Research Institute, Tennessee, US, discussed molecular mechanism and clinical evidence on the use of trastuzumab deruxtecan (T-DXd; Enhertu^®, Daiichi Sankyo & AstraZeneca) in pretreated HER2-low mBC.

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

13 Jan 2025 by

Patients HER2-positive (HER2+) breast cancer (BC) who achieve pathological complete response (pCR) have significantly better event-free survival (EFS), yet pCR cannot overcome the prognostic impact of baseline tumour size and nodal status. At an industry-sponsored symposium, Professor Michael Untch of Obstetrics and Gynaecology Department of Helios Hospital in Berlin, Germany, discussed considerations behind treatment decisions in post-neoadjuvant HER2+ early BC and data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), in this setting.

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

13 Jan 2025

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025 by

A 45-year-old nonsmoking, non-drinking Chinese male with good past health presented in 2019 with haematuria. He was initially diagnosed with non–muscle invasive urothelial carcinoma (UC) of the bladder. Transurethral resection of bladder tumour (TURBT) was performed in June and August 2019, followed by three courses of intravesical Bacillus Calmette-Guerin between September 2019 and May 2020. His baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 1.

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

06 Jan 2025 by

A 35-year-old premenopausal female who was otherwise healthy presented in July 2022 with a mass in the left breast and palpable lymph nodes (LN) in the left axillary area. She was asymptomatic, and her Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 0–1.

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

06 Jan 2025

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

06 Jan 2025 by

A 48-year-old premenopausal female presented in July 2021 with a self-detected nodule in her left breast, which she had noticed 1 week ago. Upon physical examination, a 2 cm mass in the left breast and a 2 cm lymph node (LN) in the left axilla were palpable. Further diagnostic workup revealed an irregular-shaped mass measuring 18 x 12 mm with lobulated edges and an enlarged LN of 24 x 13.9 mm in the left axilla, without distant metastasis. Biopsy of the breast mass showed invasive carcinoma that was HER2-positive, oestrogen receptor (ER)–negative and progesterone receptor (PR)–negative, with a Ki-67 level of 50 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT1N1M0).

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

06 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Second-line antibody-drug conjugate in a patient with HR-positive, HER2-low advanced breast cancer

Second-line antibody-drug conjugate in a patient with HR-positive, HER2-low advanced breast cancer

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

Treatment decisions in post-neoadjuvant HER2-positive early breast cancer

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

Early initiation of extended adjuvant therapy in a high-risk patient with early-stage HER2-positive breast cancer

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy

A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy